152 related articles for article (PubMed ID: 1420504)
1. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study.
Miller KB; Kim K; Morrison FS; Winter JN; Bennett JM; Neiman RS; Head DR; Cassileth PA; O'Connell MJ
Ann Hematol; 1992 Oct; 65(4):162-8. PubMed ID: 1420504
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM.
Natarajan-Amé S; Park S; Ades L; Vey N; Guerci-Bresler A; Cahn JY; Etienne G; Bordessoule D; Ravoet C; Legros L; Cheze S; Stamatoullas A; Berger E; Schmidt A; Charbonnier A; Chaury MP; Braun T; Fenaux P; Dreyfus F;
Br J Haematol; 2012 Jul; 158(2):232-237. PubMed ID: 22571447
[TBL] [Abstract][Full Text] [Related]
3. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
Fukuhara T; Miyake T; Maekawa I; Kurosawa M; Suzuki S; Noto S; Mori A; Chiba K; Toyoshima T; Hirano T; Morioka M; Tsutsumi Y; Okabe M; Kakinoki Y
Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057
[TBL] [Abstract][Full Text] [Related]
4. [Effect of low-dose Ara-C regimen on myelodysplastic syndrome (MDS)].
Kuriyama K
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-2):1198-204. PubMed ID: 3164177
[TBL] [Abstract][Full Text] [Related]
5. [Clinical effects of low-dose Ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes].
Kanamori H; Maruta A; Fukawa H; Harano H; Kodama F; Miyashita H; Matsuzaki M; Noguchi T; Murata T; Hashimoto Y
Rinsho Ketsueki; 1991 Feb; 32(2):108-14. PubMed ID: 2027236
[TBL] [Abstract][Full Text] [Related]
6. Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group Trial (E5483).
Robles C; Kim KM; Oken MM; Bennett JM; Letendre L; Wiernik PH; O'Connell MJ; Cassileth PA
Leukemia; 2000 Aug; 14(8):1349-53. PubMed ID: 10942228
[TBL] [Abstract][Full Text] [Related]
7. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
8. Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.
Heidel F; Cortes J; Rücker FG; Aulitzky W; Letvak L; Kindler T; Huber C; Döhner H; Kantarjian H; Fischer T
Cancer; 2007 Mar; 109(5):907-14. PubMed ID: 17285599
[TBL] [Abstract][Full Text] [Related]
9. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
Cortes JE; Heidel FH; Hellmann A; Fiedler W; Smith BD; Robak T; Montesinos P; Pollyea DA; DesJardins P; Ottmann O; Ma WW; Shaik MN; Laird AD; Zeremski M; O'Connell A; Chan G; Heuser M
Leukemia; 2019 Feb; 33(2):379-389. PubMed ID: 30555165
[TBL] [Abstract][Full Text] [Related]
10. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
Lee ST; Jang JH; Suh HC; Hahn JS; Ko YW; Min YH
Am J Hematol; 2001 Dec; 68(4):237-45. PubMed ID: 11754412
[TBL] [Abstract][Full Text] [Related]
11. Low-dose Ara-C in myelodysplastic syndromes and acute nonlymphoid leukemia. Experience with seven patients.
Bruzzese L; Abbadessa A; Ottaiano L; Arcidiacone G
Haematol Blood Transfus; 1987; 30():315-21. PubMed ID: 3623239
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.
Gerhartz HH; Marcus R; Delmer A; Zwierzina H; Suciu S; Dardenne M; Solbu G; de Witte T; Jacobs A; Visani G
Leukemia; 1994 Jan; 8(1):16-23. PubMed ID: 8289481
[TBL] [Abstract][Full Text] [Related]
13. Combination of low-dose cytarabine and 13-cis retinoic acid in the treatment of myelodysplastic syndromes.
Ho AD; Martin H; Knauf W; Reichardt P; Trümper L; Hunstein W
Leuk Res; 1987; 11(11):1041-4. PubMed ID: 3320577
[TBL] [Abstract][Full Text] [Related]
14. [Effects of low dose Ara-C regimen in acute leukemias and RAEB].
Kohno T; Nagai K; Tsukazaki K; Jinnai I; Tomonaga M; Ichimaru M; Tagawa M
Rinsho Ketsueki; 1989 May; 30(5):638-43. PubMed ID: 2795877
[TBL] [Abstract][Full Text] [Related]
15. Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia Group.
Gerhartz HH; Marcus R; Delmer A; Zwierzina H; de Witte T; Jacobs A; Visiani G; Fiere D; Sonneveld P; Labar B
Infection; 1992; 20 Suppl 2():S116-23. PubMed ID: 1493935
[TBL] [Abstract][Full Text] [Related]
16. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
[TBL] [Abstract][Full Text] [Related]
17. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group.
Zwierzina H; Suciu S; Loeffler-Ragg J; Neuwirtova R; Fenaux P; Beksac M; Harousseau J; Nuessler V; Cermak J; Solbu G; Willemze R; de Witte T; Amadori S;
Leukemia; 2005 Nov; 19(11):1929-33. PubMed ID: 16151466
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia.
Weihrauch MR; Staib P; Seiberlich B; Hoffmann M; Diehl V; Tesch H
Leuk Lymphoma; 2004 Apr; 45(4):699-704. PubMed ID: 15160942
[TBL] [Abstract][Full Text] [Related]
19. A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes.
Venditti A; Tamburini A; Buccisano F; Scimò MT; Del Poeta G; Maurillo L; Cox MC; Abruzzese E; Tribalto M; Masi M; Amadori S
Ann Hematol; 2000 Mar; 79(3):138-42. PubMed ID: 10803936
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase II trial of low-dose aclarubicin vs very low-dose cytosine arabinoside for treatment of myelodysplastic syndromes.
Harada M; Shibuya T; Teshima T; Murakawa M; Okamura T; Niho Y; Gondo H; Hayashi S; Akashi K; Tamura K
Leuk Res; 1993 Aug; 17(8):629-32. PubMed ID: 8355505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]